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Prostate-speciﬁc PTen deletion in mice
activates inﬂammatory microRNA
expression pathways in the epithelium
early in hyperplasia development
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Abstract
PTen loss is one of the most frequent events in prostate cancer both at the initiation stage and during late stage
metastatic development. The mouse model of prostate-speciﬁc probasin-mediated Pten deletion leads to prostate
intraepithelial neoplasia (PIN) leading to adenocarcinoma. Using this model, we analysed the miR and mRNA
transcriptome proﬁle of Pten−/− PIN versus wild type age-matched prostate tissues and analysed the effects of Pten loss
on miR expression in the early neoplastic process. At the PIN stage, Pten loss signiﬁcantly changed the expression of
over 20 miRNAs and over 4000 genes. The observed miR expression indicated a strong immunological cohort, which is
seen in many human and mouse cancers and is thought to derive from inﬁltrating B and T immune cells. However,
upon in situ hybridisation, these immunologically related miRs did not correlate with immune cell location, and
emanated from the prostate epithelium itself and not from the associated immune cells present. Growing Pten−/−
prostate cells in culture showed that the overexpressed miRNAs seen in Pten−/− were directly in response to the
overactive PI3 kinase pathway and were in part responsible in reducing target gene expression levels. Inhibition of PI3
kinase downstream regulators, or re-introducing wild type PtencDNA reduced miR overexpression resulting in increased
miR target gene expression. MiR inhibitors also showed this pattern, and synergised with an mTORC1 inhibitor. Overall,
Pten deletion in the prostate epithelium activated a cohort of inﬂammation-related miRs usually associated with
immune responses from B and T cells. These oncomiRs may then accelerate carcinogenesis.
Introduction
MicroRNAs (miRs) are involved in many diseases,
including prostate cancer (PCa), and are being developed
as predictive and prognostic markers of disease, or indeed
as therapies. miRs are small RNAs that associate with 3′
untranslated regions of speciﬁc mRNAs causing degra-
dation or translational inhibition1,2. Approximately 30%
of genes are thought to be controlled by miRs3. MiRs can
regulate several mRNAs and each mRNA is regulated by
several miRs, leading to complex interactions. MiRs
regulate diverse biological events, from cell division,
morphology to tissue development and differentiation.
PCa, the most common male cancer in the developed
world is a leading cause of mortality4, but with a relatively
unknown aetiology with age, diet and ethnicity being
strong risk factors. Prostate carcinogenesis is linked to
chronic inﬂammation often caused by high dietary fats
and heterocyclic amines or unknown pathogenic infec-
tions5. By the time PCa becomes symptomatic, hormonal
therapy or invasive surgery may be the only avenues
available, indicating a clinical need for early disease
detection and to identify genetic changes earlier.
Long term exposure to chronic inﬂammation has been
linked to cancer, and miRs are strongly associated with
the inﬂammatory response. Several miRs are regarded as
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being immune cell modulators or induced by immune cell
responses, e.g., miR-155 is induced in the macrophage6
and miR146 in monocytes7 respective inﬂammatory
responses, and they can modulate both the innate and
adaptive immune systems8,9. Several authors have put
forward models which involve oncomiRs secreted by
cancerous tissues (via exosomal transfer or Aurgonaute2-
bound) being detected by the immune cell TLR-8 (Toll
like receptor) which trigger an inﬂammatory response
involving IL-6 and TNFα, which can accelerate tumour
growth10,11. However, high levels of miR expression in
tumour tissue have been attributed as immune cell
derived—as a consequence of inﬂammatory signalling,
and it is unclear how much miR cross-talk occurs between
immune and tumour cells. Therefore, identifying the
speciﬁc cellular source of the miRs is also of paramount
importance, as is their downstream effects on the
expressed mRNA transcriptome.
In cancers such as PCa, with unknown aetiology,
knowing the primary source of the miR signalling may be
important. Oncogenic pathways can activate several
transcription factors—each able to upregulate a cohort of
microRNAs, each able to drive forward carcinogenesis.
However, immune cells responding to chronic inﬂam-
mation within a non-transformed tissue may eventually
promote carcinogenesis with the concurrent/co-inci-
dental activation of miR responses.
Proﬁling experiments using human PCa samples show a
high degree of miR heterogeneity—due to variance in
sample collection, processing and the oncogenes/tumour
suppressors driving the disease12–14, as well as potentially
confounding clinical issues. Additionally, samples of
human early PCa or prostate intraepithelial neoplasia are
difﬁcult to obtain due to few surgical resections at this
asymptomatic stage.
High-grade prostatic intraepithelial neoplasia (PIN) is
accepted as a plausible precursor of PCa based on clinical
and histologic features; both share the same molecular
alterations and develop from the androgen receptor (AR)
positive luminal epithelial cell layer and can include
TMPRSS215 fusions and PTEN deletions16. PTEN is one
of the most frequently mutated/deleted genes in human
cancers, found in 30%+ of all human primary PCas, and
60%+ of higher grade metastatic lesions17–19. Evidently,
PTEN may have multiple roles both in tumour initiation
and tumour progression.
The PI3/AKT pathway controls important pathways
in cell cycle regulation, proliferation, and cancer,
and activates proteins and transcription factors which
function in proliferative pathways along with phosphoi-
nositides (PIP3) with second messenger functions
20,21.
PTEN (phosphatase and tensin homologue deleted on
chromosome 10) functions to antagonise the PI3/AKT
pathway. PTEN is a phosphatase which catalyses the
dephosphorylation of the 3′ phosphate of the phosphati-
dylinositol (3,4,5)-trisphosphate (PIP3), resulting in the
inhibition of the AKT signalling pathway22,23. In late
stage PCa, when hormonal therapeutic avenues become
ineffectual, the PI3/AKT pathway (activated by PTEN
loss) remains an active therapeutic intervention avenue,
targeting one of the downstream PI3/AKT substrates
namely the mammalian target of rapamycin (mTOR).
Wang et al. established Ptenloxp/loxp:Pb-Cre4 mice,
which have conditional Pten alleles deleted by a Probasin
(Pb) promoter-driven Cre recombinase, limiting Pten
deletion to the prostatic epithelial layer24. Pten deletion
leads to enlarged prostate glands with an accelerated
development of mouse PIN by 10 weeks, with invasive
adenocarcinoma thereafter. Although the mouse prostate
structure is different to human, there are several points of
commonality—speciﬁcally with the glandular epithelial
AR-driven structure.
Here we have utilised this Pten knock out mouse model,
and epithelial cells derived from it, to study the source and
production of speciﬁc miRs in the development of PIN and
to assess whether certain miRs may signal the onset of
early PCa, and how they may promote the disease.
Results
Characterisation of mouse prostate tissues
We utilised the Pten-/- model for our primary studies as
factors, e.g., age, diet, stage, genetics, tissue collection and
processing could be kept tightly controlled. Additionally,
mice would be kept in a sterile environment with no
mating partners—minimising or ruling out any acquired
pathogenic sources of prostatitis.
To investigate miR expression in Pten deletion-induced
prostate tissue at PIN, we collected prostate tissues from
Ptenloxp/loxp;PBCre4+ve—(henceforth called Pten−/− or
Ptenko) mice and compared them to prostate tissues of age
matched Ptenloxp/loxp;PBCre4-ve essentially wild type mice.
8 Pten ko and 11 Pten wild type mouse prostate tissues
were obtained.
Pten−/− prostate tissue examination revealed hyperpla-
sia and characteristics associated with PIN (see Fig. 1a).
No invasion outside the prostate capsule was observed.
The Pten deletion was validated by quantitative poly-
merase chain reaction (qPCR; see Fig. 1b, c). The prostate
epithelium-speciﬁc dysregulation was also evaluated by
immunostaining with the prostate epithelial marker—AR,
see Fig. 1d. Phospho-Akt expression was also elevated in
the Pten−/− tissues, see Fig. 1e, f, indicative of an over-
active Akt pathway.
Identiﬁcation of microRNAs whose expression is changed
in Pten−/− mouse prostate tissue
We examined the miR expression (750+ miRs) from a
cohort of prostate tissues from both groups. Four age-
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Fig. 1 Characterisation of the Pten deletion mouse prostate tissue. a Hematoxylin and eosin staining of formaldehyde ﬁxed wax-embedded
prostate tissues taken from the Ptenloxp/loxp; Pb-Cre4+ve (Pten KO) and Ptenloxp/loxp (Pb-Cre4-ve) 'wild type' mice. b Boxplot showing qPCR analysis results
of Pten mRNA levels (at exon 5) from total RNA obtained from Pten−/− and wild type mouse prostate tissues (results shown for the anterior prostate =
AP). c Boxplot showing qPCR analysis results of Cre expression levels from total RNA obtained from Pten−/− and wild type mouse prostate tissues.
Results represent the means of n = 11 tissues measured in triplicate. d Immunohistochemical staining for the prostate epithelial marker—androgen
receptor (AR) in Pten−/− and wild type mouse prostates. e Immunohistochemical staining for phospho-AKT in Ptenko and Ptenwt tissue sections. f
Western blot of phospho-AKT and total AKT from protein extracts of mouse prostate tissues
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matched pairs of mouse tissue were used for global
microRNA expression analysis. Samples did not show a
high degree of variation in global sample Ct values indi-
cating sample reproducibility.
From the 750 microRNAs studied, 452 were detectable
and 170 were undetectable in both groups (see Fig. 2a).
Forty ﬁve microRNAs showed Pten−/−-speciﬁc
expression, and 83 showed a complete loss of expression
in the Pten−/− prostates (see Fig. 2a). Figure 2b shows
the expression characteristics of all 750 miRs
compared to wild type prostate tissue. Figure 2c shows a
volcano plot of all microRNAs along with their
expression levels and p values. From the 452 miRs
expressed in both groups, 39 miRs showed expression
with strong p values <0.05 (see Fig. 2c and Table 1).
Sixteen miRS were found to be signiﬁcantly upregulated
in Pten −/− prostates (2-fold or higher) and ﬁve were
found to be signiﬁcantly downregulated (−2-fold or
lower). A list of the top 20 miRs lost or expressed in
Pten-/-, uniquely, are given in Supplementary Table A,
although no p values are given due to the lack of
expression in the other group. The microRNAs
mmu-miR-155 and mmu-miR-132 were validated by
qPCR of the whole cohort of mouse tissues (ko= 8,
wt= 11) (see Fig. 2d, upper panel) and were found to be
overexpressed by over 3-fold in Pten−/− prostates.
Similarly mmu-miR-133a and 181 were found to be
reduced (see Fig. 2d, lower panel).
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Fig. 2 MicroRNA expression levels are signiﬁcantly changed in Pten deletion-driven prostate intraepithelial neoplasia (PIN). a Venn diagram
indicating expressed and non-expressed miRs in the Pten−/− (KO) and wild type (WT) prostate tissues. Data obtained from the Taqman low density
array n = 4. b Bar chart indicating the expression levels of all 750 miRs in the Pten−/− prostate tissues—expressed as log2 relative quantiﬁcation (RQ)
over wild type. c Volcano plot indicating the expression proﬁle and p values of all 750 miRs from the LDA card analysis (dotted line indicates p value
at 0.05). d Independent validation of the expression levels of a sample of miRs by qPCR, in the main complete cohort. Mir expression was normalised
to sno-RNA-234 & 202. Data represent the means the replicates from n = 8 wt and 11 ko tissue samples
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Identiﬁcation of genes whose expression is changed in
Pten−/− mouse prostate tissue
To analyse the effect of the Pten-/--induced changes in
miR expression on the mRNA transcriptome, we carried
out RNA-seq on the same RNA samples as analysed in
Fig. 2 (N= 4 in each group). Figure 3a shows a map of the
RNA-fragment aligned reads overlaid on the gene struc-
ture of mouse Pten and together with Fig. 1c conﬁrms the
strong reduction or absence of reads at Pten exon 5 (the
remainder of exon 5 reads presumably coming from
remaining contaminating stromal, endothelial, immune
and blood cells etc not expressing Pb-Cre). Hierarchical
cluster analysis on the four replicates showed a good
separation between sample groups (see Fig. 3b). We
observed that at PIN, the Pten deletion resulted in the
change of over 4000 genes (p> 0.05, 2-fold change) as
summarised in the heat map with hierarchical clustering.
3321 genes showed more than +2-fold increase in
expression, while 831 genes showed a −2-fold reduction
in expression in Pten−/− prostates. The top 20 up and
down regulated genes are given in Supplementary
Tables B–E. Supplemental Fig. 1a shows q-PCR validation
of the expression of a subset of these genes in the original
cohort set (ko= 8, wt= 11). When compared to the data
presented by Wang et al., overall there was a strong
agreement in the gene expression proﬁles for both studies
(R= 0.76), with the directionality of gene expression
being very similar (see Supplemental Fig. 1b).
Functional categories and pathways for genes altered by
Pten deletion in the prostate
Functional gene ontology analysis (KEGG) of the 4000
genes changed in the Pten−/− prostate tissue clustered very
strongly into key pathways, mainly centred upon immuno-
logical responses, e.g., host tissue hyper-proliferation,
inﬂammatory signalling and infection responses (see Fig. 3c).
These gene pathways were driven by Toll-like receptors,
interferon-γ (IFNG) and prostaglandin receptor (PTGER2).
Upstream regulator analysis (Igenuity Knowledge Base)
revealed several key transcription factor candidates likely
for the gene expression pattern observed including AR,
NF-κΒ, HIF1α, Stat1&3, Fos, Jun, YY1 and Myb. Addi-
tionally, the nuclear receptors PPAR-γ/α and RAR-α/β/γ
and RXRα had signiﬁcant inputs (see Fig. 3d).
The gene set observed in the RNAseq analysis (p> 0.05,
-/+2), was then analysed for micro-RNA binding sites.
The average gene expression levels were plotted against
each signiﬁcantly regulated microRNA target. Gene
expression data showed that mRNAs with target regions
in their UTRs for the strongly overexpressed microRNAs,
e.g., mir-155, 223 showed an average reduction in gene
expression within Pten−/− prostates. Genes with binding
sites for low or under-expressed miRs (low RQ) showed
less downregulation (see Fig. 3e).
Table 1 MicroRNA expression values (relative
quantiﬁcation) from PTen−/− mouse prostates compared
with wild type
MicroRNA name RQ value p value
mmu-miR-155 9.11 0.007
mmu-miR-223 7.74 0.001
mmu-miR-146a 4.91 0.012
mmu-miR-132 4.87 0.025
mmu-miR-142-3p 4.53 0.004
mmu-miR-135b 4.33 0.027
mmu-miR-146b 4.20 0.001
mmu-miR-150 2.64 0.016
mmu-miR-34b-3p 2.64 0.007
mmu-miR-31 2.63 0.045
mmu-miR-16 2.47 0.026
mmu-miR-126-3p 2.47 0.017
mmu-miR-210 2.16 0.034
rno-miR-532-5p 2.14 0.008
mmu-miR-342-3p 2.13 0.035
mmu-miR-409-3p 2.11 0.026
mmu-miR-139-5p 1.70 0.010
mmu-miR-339-3p 1.68 0.014
mmu-miR-134 1.60 0.037
mmu-miR-21 1.57 0.048
mmu-miR-411 1.53 0.045
mmu-miR-429 1.41 0.026
mmu-miR-127 1.40 0.032
mmu-miR-191 1.37 0.046
mmu-miR-188-5p 1.37 0.024
mmu-miR-186 1.33 0.001
mmu-miR-434-3p 1.30 0.031
mmu-miR-199a-3p 1.27 0.036
mmu-miR-431 1.24 0.041
mmu-miR-532-3p 1.23 0.048
mmu-miR-126-5p 1.03 0.012
mmu-miR-130a 0.87 0.025
mmu-miR-376c 0.85 0.050
mmu-miR-324-5p 0.68 0.004
mmu-miR-384-5p 0.25 0.030
mmu-miR-221 0.24 0.008
rno-miR-1 0.08 0.028
mmu-miR-1 0.08 0.014
mmu-miR-375 0.05 0.024
List includes all microRNAs with p values of >0.05
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The source of microRNA overexpression within the Pten−/−
prostate originates from the inﬂammatory prostate
epithelia and from inﬁltrating immune cells
We analysed the tissues by immunohistochemical
staining for the upstream regulatory markers indicated by
the Ingenuity pathways. This would allow us to determine
the origin and drivers of miR overexpression in the tissue,
i.e., Pten−/− driven or immune cell derived. Gene ontol-
ogy and upstream factor analysis showed that the tran-
scription factors AR, STAT3, NFκβ, HIF1α, and RAR/
RXR as well as immunological mediators, e.g., interferon-
γ, toll-like receptors (TLR7-8) and prostaglandin recep-
tors were strongly implicated in the gene expression
pattern observed.
Immunohistochemical analysis of wild type and Pten−/−
prostate sections showed speciﬁc staining for IFN-γ,
NF-κβ and STAT3 within the glandular epithelium of the
Pten−/− tissues. (see Fig. 4a, b). HIF1α levels were slightly
higher in Pten−/− tissues (Fig. 4b) and AR levels were
equally strong in both tissue types (see Fig. 1d).
When analysing the immune cell inﬁltration within
these tumour sections we observed that both CD3+ve
T cells and CD45R+ve B cells were increased within the
stromal compartment of the Pten−/− prostate tissue (10%
+ of cells). Additionally, we observed an increase number
of monocytes and macrophages via haematoxylin and
eosin staining (see Supplemental Fig. 2). However, the
immune cell inﬁltration did not correlate with the staining
pattern seen for the inﬂammatory markers IFNγ, NFκβ,
STAT3 or the epithelial marker AR. A low level of
immune cell inﬁltration was seen within the hyperplastic
epithelial cell layers (1% of cells approx.) (see Fig. 4c, d),
whereas immune cells were located in stromal clusters,
near blood vessels or were peripheral. Upon in situ
hybridisation with anti-miR-155 and mir-21 probes,
staining for miR expression was seen most strongly in the
epithelial layer (see Fig. 4e), and not in the stromal,
endothelial or immune cell inﬁltrates, indicating the
source of the overexpressed miRs to be from the epithelial
cells (as highlighted in the AR stained adjacent tissue
section for epithelial cell reference). In wild type prostate
sections—individual immune cells could be seen staining
positive for miR-155/21 (0.5–1% immune cell inﬁltrate)
within the normal unstaining prostate epithelium (see
Fig. 4e). Interestingly, miR levels in the serum of the mice
harbouring the Pten−/− prostate tissue showed elevated
levels of the overexpressed miRs, although the exact cel-
lular source of the serum miR cannot be speciﬁcally
identiﬁed (see Fig. 4f).
Pten deletion drives miR overexpression from the
epithelium in vitro
To investigate whether the overexpressed miRs
observed in the Pten−/− tissue were driven by Pten dele-
tion or whether due to responding localised inﬂammatory
immune cell involvement, we studied the Pten−/− pros-
tate epithelial cells in isolation, in culture.
We cultured isolated prostate epithelial cells from the
Pten−/− mice which expanded into a cell line rapidly
within 4–5 passages (see Fig. 5a). The Pten and AR levels
were measured by qPCR, as well as compared to wild type
prostate tissue and mouse prostate Pten−/− cells acquired
from the ATCC cell bank (see Fig. 5b). The tissue-derived
Pten−/− cells were indistinguishable from the ATCC-
PTEN-CAP8 cell line by these criteria. No CD3 or CD45R
expression could be detected on western blot extracts
(data not shown). MiR expression was high in these
cell lines when compared to wild type tissue
(see Supplemental Fig. 3).
To evaluate the effect of Pten on miR expression
in vitro, we than stably transfected the Pten−/− cells with a
pEF6-PtenWT vector, to re-introduce wild type Pten
expression. An increase in full-length PTEN protein was
observed, and cells also showed the inhibition of the
phospho-AKT pathway in these wild type Pten expression
cells (see Fig. 5c). These cells also showed a reduced cell
growth (see Fig. 5d).
The re-introduction of wild type Pten, strongly reduced
the expression of the overexpressed miRs 132, 150, 155,
223 but increased the expression of the previously
downregulated miRs-375, mir-377 and miR-1 (see
Fig. 5e). Wild type Pten also increased the sensitivity of
(see ﬁgure on previous page)
Fig. 3 Pten deletion signiﬁcantly alters the expression of over 4000 genes in Pten−/− prostate intraepithelial neoplasia (PIN). a Heat map of
mRNA transcript fragment reads from Ptenloxp/loxp; Pb-Cre4+ve (Pten KO) and Ptenloxp/loxp (Pb-Cre4-ve) 'wild type' prostate-derived mRNA (N = 4
replicates) overlayed on the gene structure of mouse Pten (RefSeq, 2015)—indicating the absence and/or reduction of Pten RNA fragments at exon 5.
b Diagram showing the hierarchical clustering analysis of the 4000+ genes either upregulated or downregulated (±2-fold, p = <0.05) showing the
four replicates (drawn in Partek). c Table indicating the most activated and inhibited upstream regulators likely to be responsible for the genetic
changes observed. Data presented from Ingenuity Upstream Regulator analysis. d Diagram indicating the shared regulatory interactions of the
transcription factors involved in the genetic changes observed in the Pten−/− prostates (drawn using http://molbiol-tools.ca/Transcriptional_factors.
htm). Font size indicates increasing interactions. e Bar chart showing the average fold change (expression) of the predicted mRNA targets of the
miRs found overexpressed (High RQ) or lost (Low RQ) in the Pten−/− RNAseq cohort. Graph is ranked according to RQ of the expressed miR of interest
(p < 0.05). Target predictions done in with www.microRNA.org and Partek (with Targetscan) software. Mir targets n = 200–600 genes approx
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Fig. 4 Inﬂammatory pathways are activated in Pten−/− prostate epithelial cells at the prostate intraepithelial neoplasia (PIN) stage. a
Immunohistochemical staining for IFN-γ and NF-κβ in Pten−/− (KO) and wild type prostate tissue. b Immunohistochemical staining for HIF1-α and
STAT3 in Pten−/− (KO) and wild type prostate tissue. Magniﬁed sections from Pten−/− shown inset on the right hand side. c Immunohistochemical
staining for CD3 and CD45R in mouse prostate tissue. d Bar graph representing the % of cells staining positive for the immune cell markers CD3 and
CD45R. Results indicate the number of staining cells in ﬁve random ﬁelds of view across the tissue section, compared to the total number of cells. e In
situ hybridisation staining for the microRNAs mmu-miR-21 and mmu-miR-155 in Pten−/− (KO) and wild type prostate tissue. Right hand side inset
panel indicates areas of epithelial AR staining for reference. f q-PCR analysis of expression levels of mmu-miR- 155, 132, 375 and 377 from the serum
of Ptenloxp/loxp; Pb-Cre4+ve (Pten KO) and Ptenloxp/loxp (Pb-Cre4-ve) 'wild type' mice. Serum miR levels were normalised to a C. elegans miR-39 spike in
control
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these cells to the rapamycin analogue Temsirolimus
(Fig. 5f). The mTOR protein regulates several down-
stream transcription factors which could be regulating the
microRNA transcription, and mTOR inhibitors can
reverse many aspects of the Pten-transformed pheno-
type25. Temsirolimus treatment resulted in the strong
reduction of miR-155, 132, 150 and 223 levels by 30–50%,
and interestingly, miRs-377 and 375, found to be down-
regulated in Pten−/− prostate tissue, showed a biphasic
response ﬁrst increasing in expression then reducing
(see Fig. 5g).
Analysing miR expression in PTenwt prostate cells trea-
ted with PI3K/PTEN modifying drugs showed that the
mTORC1 inhibitor (Tem) decreased miR-155, miR-150
and miR-132 expression, while inhibition of the ectopically
expressed wild type PTEN with the highly selective PTen
inhibitors SF1670 [N-(9,10-Dihydro-9,10-dioxo-2-phe-
nanthrenyl)-2,2-dimethyl-propanamide] and bpV(HOpic)
[Dipotassium bisperoxo (5-hydroxypyridine-2-carboxyl)
oxovanadate] increased miR expression (Fig. 6a).
When PTen−/− cells were treated with miR-155 and 132
inhibitors, we saw a modest but statistical signiﬁcant
reduction in cell growth over 4 days (−8%), compared to
mock or scrambled controls (see Fig. 6b). When com-
bined with Temsirolimus treatment we observed a
synergistic effect, where mir-155 or 132 inhibitor treat-
ment resulted in decreased cell growth and an IC50
reduction of Temsirolimus from 28 to 15 μM approx (see
Fig. 5c, d).
As well as mTOR, we also investigated other potential
drivers of miR expression, e.g., AR, NFκβ and STAT3. The
androgen induction of these microRNAs was evaluated by
treating hormonally starved PTen−/− cells (72 h) with the
synthetic androgen R1881. qPCR analysis of microRNA
levels showed that androgen-stimulated cells strongly
increased their mir-155, 223, 146a, 132 expression while
mir-375 and 377 were unaffected (see Fig. 6e). The anti-
androgen bicalutamide reduced this expression (see
Fig. 6f). The NFκβ inhibitor (non-speciﬁc) MG132
reduced mir-155, 132, and 150 expression, as did the
STAT3 inhibitor 15-DPP (see Fig. 6f).
We then validated if the downregulated genes seen in
the PTen−/− prostate cells were in fact regulated or
inﬂuenced by the aberrant Pten−/− pathway-induced miR
upregulation. In silico analysis using the miR:mRNA
expression proﬁles using six online databases (see Fig. 7a)
indicated a potential list of candidate genes—several of
which were targeted by multiple miRs, e.g., Wee1 (see
Fig. 7b).
Firstly we treated PTen−/− cells with temsirolimus,
which strongly inhibited mir-155, 132, 150 and 223
expression (see Fig. 5g). qPCR gene expression analysis
showed an increased expression of a panel of eight genes
of interest (see Fig. 7c). Similarly, the PTenwt expressing
cell line showed very similar increases in gene expression
(see Fig. 7d). We transfected Pten−/− cells with LNA-
modiﬁed miR-155 or 132 inhibitors and analysed
expression of our predicted target genes. MiR-155 inhi-
bitor treatment increased the expression of Nkx3-1, Nkd,
and Wee1, while the miR-132 inhibitor increased the
expression of Hhip, Fox2p, and Eif4a2. The proposed miR
target genes Dync1i1 and Fkbp2 showed no signiﬁcant
changes (see Fig. 7e). Mir-155 biotinylated pulldown
analysis of mRNA transcripts bound to miR-155 showed
an enrichment of Nkx3-1, Dync1i1,Wee1 and Nkd mRNA
(see Fig. 7f).
Finally we constructed ﬁreﬂy luciferase reporters fused
with either full length 3′-UTR regions of three genes of
interest, namely Wee1, NKX3.1 and Fox2p or fusions
containing the pure miR binding site for miRs 155 and
132 (see Fig. 7g). When transfected into mouse prostate
cells we measured a lower activity of the luciferase
reporter as compared to the constitutive renilla reporter,
expressed from the same plasmid, of 10–20% approx.
Further, the reduced luciferase activity of the pure miR
binding site reporters were abrogated when miR over-
expression was inhibited by temsirolimus treatment.
When we transfected expression plasmids (pEF6)
expressing Wee1, Nkx3.1 or Fox2p into mouse PTen−/−
cells we observed a modest reduction in cell growth over
6 days—indicating the normally repressive function of
these genes (see Supplemental Fig. 4).
(see ﬁgure on previous page)
Fig. 5 MiR overexpression is maintained in Pten−/− prostate epithelial cells in vitro and is inhibited by wild type Pten re-introduction and
mTOR inhibitor—temsirolimus. a Phase contrast microscope image of isolated Pten−/− cells from Ptenloxp/loxp; Pb-Cre4+ve (Pten KO) mouse
prostates. b qPCR expression levels of Pten (left hand side) and AR (right hand side) in the tissue derived from adult male Ptenloxp/loxp; Pb-Cre4+ve (Pten
KO) or wild type mice, compared to the Pten−/− mouse tissue-derived prostate cells or cells derived from the ATCC directly (Ptenloxp/loxp;Cre+ve). c
Western blot analysis of PTEN, AKT and phospho-AKT levels in Pten−/− cells stably transfected with wild type Pten (pEF6-Ptenwt expressing plasmid).
Densitometry data for p-AKT/AKT is given in the bar graph underneath. d Crystal violet cell growth assay of the Pten−/− and Pten+wt cell lines over
time (4 days). Error bars represent the means of three independent replicates. e qPCR analysis of a panel of miR expression in Pten−/− and Ptenwt cell
lines. Results represent fold change from Pten−/−. Error bars represent the standard error from three independent replicates. Expression normalised to
mouse small RNAs sno-202 and sno-234. f Crystal violet cell growth assay of PTen−/− cells (either tissue derived or ATCC) treated with increasing doses
of Temsirolimus for 96 h, compared to Pten+WT cells. Data are plotted as % survival compared to DMSO control. g qPCR analysis of a cohort of miRs
from PTen−/− cells treated with the mTORC1 inhibitor Temsirolimus (1–10 μM versus DMSO vehicle) for 16 h. Results represent fold change in
expression over DMSO vehicle
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Discussion
PTen deletion produces an overactive PI3 kinase path-
way driving forward proliferation, thus its targeting is an
attractive treatment avenue for late stage PCa that
become hormone refractory. Several clinical trials have
evaluated such agents in these PCa patients with only
Fig. 6 Re-introduction of wild type Pten into Pten−/− prostate cells and inhibition of the PI3kinase pathway reduces miR overexpression
in vitro. a qPCR analysis of miR-155, 150 and 132 expression levels in both Ptenwt and Pten−/− cells in response to treatment with mTORC1 inhibtor
Temsirolimus and PTEN inhibitors SF1670 and bpV(HOpic). b Crystal violet cell growth assay of Pten−/− tissue-derived cells transfected with a mir-155
or mir-132 inhibitor (or scrambled control) for 48 h. Data are plotted as % cell survival normalised to mock transfected cells. c Crystal violet cell growth
assay of Pten−/− cells transfected with a mir-155 or mir-132 inhibitor (or scrambled control) and treated with increasing doses of temsirolimus. Data
represent the % survival as compared to DMSO after 96 h. d Microscopy photograph of formalin ﬁxed, crystal violet stained, Pten−/− cells transfected
with miR-155 inhibitor oligo and treated with 5 or 10 μM Temsirolimus for 96 h. e qPCR analysis of microRNA expression in PTen−/− cells hormonally
starved for 72 h and then treated with R1881 (10 nM) for 8 h. Data are normalised to mouse small RNAs sno-202 and 234. f qPCR analysis of microRNA
expression in PTen−/− cells treated with MG132 (NFκβ inhibitor), 15-DPP (STAT3 inhibitor) and bicalutamide (AR antagonist) for 8 h. Data are
normalised to mouse small RNAs sno-202 and 234. *p value 0.05
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Fig. 7 (See legend on next page.)
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modest success. However, patient stratiﬁcation for PTen
status is not currently routine.
Although structurally different, mouse and human
prostates are histological similar as are the drivers of
prostate gland development. Prostate epithelial cell-
speciﬁc PTen deletion in the mouse leads to the devel-
opment of hyperplasia and PIN, leading to adenocarci-
noma and advanced disease. The abnormal prostate
growth is initially hormone sensitive, which also become
refractory with time—recapitulating several aspects of the
human disease.
Downstream effects of PTen−/− on gene expression
We examined the effect of PTen loss in the mouse
prostate on expression of mRNA and miRNAs. Even at
the PIN stage, we observed a signiﬁcant change in over
4000 genes and up to 40 miRs.
The upregulated microRNAs found here have
been extensively identiﬁed in disease and cancer-related
pathways. However, several of our overexpressed miRs
including miRs-155, 146a/b, 132, 223, 21 and 16 have also
been identiﬁed as being Toll-like receptor-inducible
(reviewed in ref. 26), and several identiﬁed as transcribed
by NF-κΒ and Fos/Jun27. MiR-155, our highest over-
expressed miR, is conserved across mammals28. It is
prominently expressed across haematopoietic cells and
identiﬁed as an oncomiR in haematological malignancies,
breast, lung and colon cancer29. MiR-155 is a consistent
feature of mammalian inﬂammatory responses6, often
initiated by Toll-like receptor pathways. However,
miR-155 has been investigated in PCa, and found to be
upregulated, with roles targeting TGFβ/SMAD, Annexin7
and the mismatch repair genes hMLH1/hMSH630–32
in conjunction with miR-21—also upregulated here.
Other targets include genes involved in apoptotic
resistance and the homeobox-containing transcription
factor NKX3-1—discussed below. MiR-155 has also
been implicated in reprogramming normal tumour-
adjacent ﬁbroblasts to cancer associated ﬁbroblasts via
exosome signalling in both prostate and pancreatic
cancers33,34—relevant as miR-155 was increased in the
sera of Pten−/− mice.
Other overexpressed miRs found in our study have also
been strongly implicated in PCa. MiR-132 expression is
associated with inﬂammation, inducing proliferation of
endothelial cells in the tumour environment35. Mir-223
has been found to be upregulated in PCa tissues36, and the
oncomiR miR-21, is associated with poor biochemical
recurrence-free survival in PCa patients37. High mir-150
expression is positively correlated with tumour recurrence
and metastasis38.
The downregulated or lost miRs in our study, such as
miR-1 and its cluster partner miR-133, are tumour sup-
pressor miRs, previously identiﬁed as consistently down-
regulated in primary prostate tumours39. MiR-375, also
identiﬁed as a tumour suppressor40 showed a strong
downregulation our study.
Inﬁltrating immune cells did show some
mir155 staining but their numbers and locations did not
correlate with the staining pattern observed. We observed
that these miRs were produced very early in prostate
hyperplasia, and are derived from the epithelial cells
themselves. They are secreted, and may inﬂuence sur-
rounding cell growth via inﬂammatory interactions with
the immune system and trigger oncogenic pathways in the
complex primary tissue environment. Although there is a
strong crossover with inﬂammatory responses for several
of the overexpressed miRs in our study, these have also
been identiﬁed as overexpressed in cells growing in vitro
by ourselves and other groups. OncomiR expression is
retained when cells are removed from their primary tissue
of origin, and here we have shown that they are primarily
driven by events such as PTen loss, and not as a result of
immune cell signalling. Human prostate cells growing in
culture showed highest miR-155 levels in the more
aggressive cell lines, e.g., PC3 (see Supplemental Fig. 5).
Gene analysis and pathway enrichment
Pathway enrichment analysis of genes in PTen−/− tissue
showed clustering upon carcinogenesis and
(see ﬁgure on previous page)
Fig. 7 Identiﬁcation of mRNAs targeted by the inﬂammatory miRNAs in Pten−/− cells. a Schematic diagram of the computational pathways
utilised to predict miR:mRNA interactions/targets. b Table of the ﬁve most likely downregulated mRNA targets predicted by over 4/6 miR databases. c
qPCR analysis of a cohort of genes from Pten−/− tissue-derived cells treated with 10 μM temsirolimus for 24 h. Gene expression is normalised to Rpl19,
Gapdh and β-actin, and then plotted as fold change over DMSO treatment. d qPCR analysis of a cohort of genes from either Pten−/− or Pten+WT cells.
Gene expression is normalised to RPL19, GAPDH and β-actin, and then plotted as fold change over Pten−/−. e qPCR analysis of a cohort of genes from
Pten−/− tissue-derived cells transfected with miR inhibitor oligos (or mock transfected or transfected with scrambled oligo). Left hand side =miR155
inhibitor, right hand side =miR132 inhibitor. Gene expression is plotted as fold increase/decrease over untreated cells (normalised to Rpl19, β-actin
and Gapdh). f qPCR of a cohort of genes from RNA puriﬁed from Pten−/− cells transfected with a mmu-mir-155 biotinylated mimic and RNA pulldown
assay using streptavidin beads. Cells were transfected with biotinylated scrambled control oligo. Data are normalised as % pulldown compared to
mock transfected cells. g Left hand side—schematic diagram of the luciferase-3′-UTR plasmid constructs and 3′miR binding site luciferase fusions.
Right hand side—Dual luciferase assays from extracts of Pten−/− (KO) and Pten wild type (WT) mouse prostate cells transfected with the luciferase UTR
constructs or miR binding site constructs for 48 h. For miR fusion reporters Pten KO or WT cells were also treated with 10 μM temsirolimus. Luciferase
activity is normalised to the constitutively active renilla luciferase
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immunomodulatory pathways. Upstream analysis of both
transcription factors and other regulatory molecules
indicated a strong involvement of AR, STAT1&3, NF-κΒ
and HIF1α as being responsible for the gene expression
pattern. PTEN regulates and increases the activity of these
transcription factors.
PTEN activates HIF1α via the inactivation of Forkhead
transcription factors41. HIF1α activation is an early event
in prostate carcinogenesis, including mouse models42–44,
and studies have also demonstrated that hypoxic
responses are signiﬁcantly increased in PTen null prostate
cells—triggering cytokine response networks45.
STATs represent downstream effector transducers of
the inﬂammatory cytokine and growth factor signalling
pathways46 via mTOR and are implicated the promotion
and progression of PCa47,48. STAT3 links inﬂammatory
pathways to cancer development via miR-21, miR-155,
miR-16 upregulation and NK-κΒ49,50.
AR is essential for prostate functional and develop-
mental pathways. AR may be inactivated by an overactive
AKT pathway51,52. Indeed, a strong downregulation in
several AR-regulated genes, e.g., Nkx3-1, Probasin, and
Tgm4 was seen, without AR protein levels changing.
However, conversely the miRs studied here showed a
strong upregulation by androgen-activated AR. AR has
also been strongly correlated with upregulation of miR at
the transcriptional level and during mature strand pro-
cessing53,54—therefore the functioning of the AR remains
conﬂicting in the PTen−/− prostate.
Upstream regulatory analysis predicted that interferon-
γ, Toll-like and prostaglandin receptors to be activated,
resulting in the enrichment of immunological response
pathways seen. PCa progression in humans has been
strongly associated with chronic inﬂammation55–57, and
Garcia et al.58 showed that loss of PTen in the mouse
prostate epithelium leads to a signiﬁcant upregulation of
genes within the inﬂammatory and cytokine-to-cytokine
signalling network. Other cancers with PTen deletions
show similar patterns59,60.
miRs may regulate up to 90% of the genome61. Overall
the miR:mRNA correlations showed on a broad level that
the overexpressed miRs in PTen−/− showed a signiﬁcant
reduction in expression of their target genes, and a 'sig-
nature' of the overexpressed miRs could be seen in the
regulated mRNA population.
Other gene downregulation changes in the PTen−/−
prostate included—gasdermin family members, involved
in inﬂammatory defence; Bmp7—involved in prostate
morphological development; and Kiss1—involved in
suppressing metastasis. Gene upregulation changes
included—Tff3 (Trefoil factor 3) an epithelial secreted
protein associated with mucosal defence, injury and car-
cinogenesis; Wnt4—essential for prostate development;
Fam129b—a WNT family regulator; Epst11—associated
with epithelial to mesenchymal transition in cancer and
Cxcl16—chemokine strongly associated with inﬂamma-
tion in PCa.
Inhibiting the PI3 kinase pathway
We tested whether the overexpressed miRs would (i),
still be highly expressed in vitro and (ii), be responsive to
PI3kinase pathway inhibitors. Additionally, we re-
introduced wild type PTen cDNA into these cells and
monitored their miR expression levels. The overexpressed
miRs were still highly expressed in vitro, and these miRs
could be reduced by Temsirolimus treatment, and by re-
expressing wild type PTen. Conversely, the previously
repressed miRs in PTen−/− cells, were increased by both
treatments—indicating a direct role of the PI3 kinase
pathway in controlling miR expression. The PTen inhi-
bitor agents SF1670 and bpV(HOpic) increased the miRs’
expression in the PTenwt cells. These treatments also
increased the expression of a previously PTen−/−—
repressed gene cohort. Blocking the activity of the target
miRs via miR-inhibitors also increased the expression of
these target genes, although to a modest level.
Some of the miRs found to be overexpressed in this study
were upregulated by the PI3 kinase pathway and are in part
responsible for the reduction of certain target genes. An
example being the miR-155 target gene—Nkx3-1, which
was previously non-detectable. Although Nkx3-1 has been
described as being silenced by methylation62,63, it is
possible that miRs also play a role in the silencing of such
genes—especially given that the luciferase-Nkx3.1 3′-UTR
fusion reporter showed a reduction in expression. Indeed
decreased NKX3-1 has been observed in areas of
prostate inﬂammation in the aging prostate, and our data
would support the role of inﬂammation-regulated miRs
(e.g., miR-155) in this process64,65.
We tested a miR-inhibitor, individually and in combi-
nation with Temsirolimus—which reduces PTen-driven
tumour subtypes in mice66. PTen is frequently mutated in
castration-resistant PCa patients and in late stage metas-
tasis67, and PI3k/mTOR inhibitors have been promised as
chemotherapeutic agents, but with limited activity68. The
miR-155 and 132 inhibitors showed a modest activity in
the PTen−/− cells, and showed synergy with Temsir-
olimus, reducing the IC50 by almost 40%.
Conclusions
Here we have observed that PTen deletion in the
prostate epithelium drives a signiﬁcant change in both
gene and miR expression—genes with signiﬁcant invol-
vement in the inﬂammatory response as well as in carci-
nogenesis. The overexpressed miRs (OncomiRs) show a
signiﬁcant effect on the gene expression proﬁle especially
for those mRNAs targeted by the oncogenic miRs.
These miRs e.g., mmu-miR-155 may further accelerate
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or cooperate in the development of carcinogenesis
by targeting and downregulating genes such as NKX3.1
and Wee1 via their 3′-UTR regions—genes known to
enhance the carcinogenic phenotype of the mouse Pten
model.
Although involved in inﬂammatory responses, the over-
expressed miRs were observed to emanate from the pros-
tate epithelium itself upon in situ hybridisation studies and
did not correlate with the location of the immune cell
inﬁltrate. Additionally, miR expression remained high when
prostate epithelial cells were grown in culture, indicating
immunological cell stimulation, was not responsible. Direct
inhibition of the PTEN signalling cascade via temsirolimus
treatment reduced miR expression signiﬁcantly as did
ectopic expression of wild type Pten. Such inhibitors
synergised with miR inhibitors to reduce cell growth, and to
re-express several previously downregulated genes.
It is interesting to note that many of the miRs found to
be overexpressed in the Pten knock out tissue overlap
with those found in prostate inﬂammatory or hyperplastic
diseases which are often thought of as being predisposing
conditions for PCa and may be strongly linked with its
aetiology. For example, miR-155 has been shown to be
upregulated in response to bacterial lipopolysacchar-
ides6,7. Thus inﬂammatory pathways driven by PTEN
or by a genuine pathogenic responses may have
signiﬁcant overlap—linking inﬂammation and cancer
development.
Synergistic agents based on miR inhibitors may prove
worthy in the future as they target the terminal down-
stream effectors of the overactive PI3k pathway and
synergise with agents working upstream, e.g., mTORC or
PI3k inhibitors—targeting this pathway from compli-
mentary directions.
Materials and methods
Mouse strains
PTenloxp/loxp; ARR2-PB-Cre mice, described pre-
viously24 were originally obtained from The Jackson
Laboratory (Maine, USA). All procedures were in accor-
dance with UK Home Ofﬁce legislation.
Tissue ﬁxation
Tissues were ﬁxed in 10% formalin for 24 h, then
dehydrated in ethanol, xylene and then processed into
parafﬁn embedded blocks, using standard procedures.
Primary cell culture
Tissue was washed in phosphate-buffered saline
(PBS) and macerated using a sterile blade. Tissue was
digested in trypsin/collagenase with continued shaking
at 37 °C. Cell suspensions were centrifuged at 1200g
for 5 min and resuspended in medium and plated out in
ﬂasks.
Cell culture
Mouse PTen−/− prostate-derived cells were maintained
at 37 °C, 5% CO2 in DMEM:Ham’s F12 medium with 10%
foetal bovine serum (First Link, Wolverhampton, UK)
supplemented with 100units/ml penicillin, 100mg/ml
streptomycin (Sigma, Dorset, UK), pituitary extract
(Lonza, Slough, UK), and 10ng/ml epidermal growth
factor.
Immunoblotting and immunohistochemistry
Standard immunoblotting and immunehistochemistry
protocols were carried out. Antibodies used were AR (N-
20, Santa Cruz, CA, USA). PTen, AKT, p-Akt, NFκβ,
IFNγ, HIF1α and STAT3 were obtained from Santa Cruz.
CD3 was from DAKO (Santa Clara, CA USA) and CD45R
was from Biolegend (San Diego, CA, USA). The Vectas-
tain avidin–biotin complex (Vector Labs, Peterborough,
U.K.) was used for detection, using diaminobenzidine
chromogenic substrate. Negative controls were included
lacking primary antibody. Images were captured using a
Leica DM1000 microscope.
In situ hybridisation
FFPE sections (5 μm), were dewaxed and re-hydrated.
Tissue permeabilisation was performed using Protease-K
2–15 μg/ml (Sigma-Aldrich, UK). Slides were washed in
diethyl pyrocarbonate (DEPC) water, and incubated in
prehybridisation solution for 60mins at 37 °C, then an
equal volume of miR probe (dig-labelled miR155/21/
scrambled—250 ng/μl), and incubated overnight. After
washing with Tris-buffered saline (TBS), slides were then
incubated with anti-digoxigenin alkaline phosphatase
antibody (1:600) (Roche) for 60mins at room tempera-
ture. Slides were washed with TBS, then alkaline phos-
phatase buffer followed by the addition of NBT/BCIP
substrate solution (Sigma Aldrich, UK) with 1 μl of 1 μM
levamisole and slides were incubated overnight. Finally,
slides were washed in water and mounted with aqueous
mountant.
RNA extraction and reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was prepared using Trizol, (Sigma) and
converted to cDNA using the SuperScript First-Strand
Synthesis system (ThermoFisher, MA, USA). RNA
quality was assessed using a Bioanalyser 2100 (Agilent
Technologies LDA, UK).
Quantitative polymerase chain reaction (qPCR)
Reactions were performed in triplicate in 96-well optical
plates on an ABI One-Step system (Applied Biosystems,
Warrington, U.K.), consisting of 2 μl cDNA, 7 μl PCR-
grade water, 10 μl 2× TaqMan Universal PCR Master Mix
(Applied Biosystems), 1 μl Taqman-speciﬁc assay probes
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for RPL19, β-actin, and GAPDH and all microRNAs
studied (Applied Biosystems). Parameters were: 50 °C
for 2 min, 95 °C for 10min, 40 cycles of 95 °C for 15 s and
60 °C for 1 min. For Cre and PTen custom designed oligo
primers were purchased (MWG Euroﬁn, Germany), with
SYBR Green PCR. Data were recorded and normalised to
GAPDH, β-actin and RPL19.
MicroRNA RT-qPCR
The rodent Megaplex pool miR-RT stem-looped pri-
mers were used for reverse transcription (Applied Bio-
systems). RNA (500ng) was reverse transcribed using the
manufacturer’s conditions. Taqman microRNA micro-
ﬂuidic arrays were used to analyse 715 common rodent
microRNAs (A&B Applied Biosystems). Data were nor-
malised using U6-snRNA, snoRNA135, snoRNA202, U87,
and Y1.
Collection and measurement of miRs from mouse blood
serum
Blood was collected from Ptenwt and Ptenko mice using
cardiac puncture under terminal anaesthesia. Blood was
collected and was allowed to clot naturally in a sterile
Eppendorf tube. Samples were centrifuged at 3000×g for
10 min to remove cellular material. The serum was then
removed and stored at −80 °C.
For RNA extraction—a standard Trizol LS protocol was
carried out (ThermoFisher), with the following mod-
iﬁcations. The Trizol LS was ‘spiked’ with Arabidopsis
thaliana miR-159a and C. elegans miR-39 mimic oligos
(1 μl/ml of 1 nM solution). 0.75 ml of Trizol LS was added
to 0.25 ml of serum for the procedure. During RNA pre-
cipitation, 1 μl of GlycoBlue (ThermoFisher) was added to
aid visualisation of the RNA pellet. Ten nanograms of
RNA was used for the reverse transcription reaction. miRs
were detected using microRNA Taqman assays from Life
Technologies. MicroRNA levels were the adjusted for any
losses using standard curves created using A. thaliana and
C. elegans miR mimic (MWG) in a standard RT reaction.
RNA-seq analysis
PolyA mRNA was isolated from total RNA using the
Dynabeads mRNA DIRECT Kit (Life Technologies, UK).
RNA fragment libraries (150–200 bp) were generated
using the Ion Total RNA-Seq kit (Life Technologies),
ligated to adaptors for cDNA synthesis and ampliﬁed
using IonXpress RNA-seq barcoded primers (5′). cDNA
libraries were clonally ampliﬁed using Ion PI template
OT2 200 kit (Life technologies, USA) on an Ion
OneTouch2 system (Life technologies) as per manu-
facturer’s instructions. Samples were processed using the
Ion Proton 200 sequencing kit and loaded onto a P1 chip
and sequenced on an Ion Proton (Life technologies) using
default parameters (single-end, forward sequencing). Base
calling, adaptor trimming, barcode deconvolution and
alignment was performed on Torrent Suite version 3.6
(Life technologies) using the STAR RNA-seq aligner
plugin. The Partek Genomic Suite 6.6 software was used
for data analysis. The RPKM normalisation method for
RNA-seq69 was used followed by a 1-way Anova test for
differential expression (from n= 4 samples per group).
MiR:mRNA correlation analysis
Genes with a greater ±2-fold change or higher with p
values of <0.05 or were captured in a database (Access,
Microsoft, USA) and merged to the predictive databases
MirBase and Targetscan, downloaded from http://www.
microrna.org and http://www.targetscan.org/mmu_61
respectively.
MicroRNA inhibitor transfection
Cells were transfected using RNAiMax (ThermoFisher)
with LNA-modiﬁed microRNA inhibitors (Exiqon, MA,
USA) at 1 μl (of 10 μM stock) per 6-well dish.
Re-expressing PTen wild type cDNA
The PTen coding region was ampliﬁed from wild type
mouse cDNA using the primers 5′-ATGACAGCCA
TCATCAAAGAGATCGTTA-3′ and 5′-TCAGACTTT
TGTAATTTGTGAATGCTGAT-3′ with Pfu polymerase
(Promega) and inserted into the pEF6-TOPO expression
plasmid (ThermoFisher), and veriﬁed by sequencing. The
plasmid was transfected into mouse PTen−/− cells using
Lipofectamine (ThermoFisher) to generate stable cell
lines under blasticidin selection.
Cloning of miR target genes and 3′-UTR regions and miR
binding sites
The coding sequence of Nkx3-1, Wee1 and Fox2 P and
their respective 3′-UTR regions were ampliﬁed by PCR
using Pfu and Taq polymerase mix (Promega) from
mouse cDNA derived from wild type mouse tissue. The
primers details are given in Supplemental Table 1. The
coding regions were cloned directly into the pEF-TOPO
expression plasmid (Life Technologies), and veriﬁed by
sequencing. The 3′-UTR regions were cloned into the
pmiR-Glo luciferase reporter plasmid (Promega) at the
Sac1/Sal1 site of the MCS downstream of the ﬁreﬂy gene
luc2. For the cloning of miR binding sites we followed the
Promega protocol and ligated duplex oligos containing
the 22 bp miR binding site, an internal Not1 restriction
site and 3′Pme and 5′Xba1 restriction sites.
Luciferase assays
Mouse cells were transfected with reporter plasmids in a
24-well plate using Lipofectamine 3000 (Life Technolo-
gies) and then treated as necessary. After 48 h, cells were
washed and lysed in passive lysis buffer (Promega) and the
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ﬁreﬂy luciferase activity measured using a luminometer.
The Promega Dual Glo luciferase assay kit was used to
measure both renilla (constitutive) and ﬁreﬂy (variable)
activity.
Biotinylated MiR Mimic Pull Down for mRNA Targets
Transfection
Cells were transfected using 200 pmol of biotinylated
miR mimic (Sigma) into 4× 106 cells using Lipofectamine
RNAiMax (Life Technologies), and incubated for 24 h.
Post transfection, cells were washed with ice-cold PBS and
lysed in 1ml of ice-cold hypotonic lysis buffer (10 mM
KCl, 1.5 mM MgCl2, 10 mM Tris-HCl pH 7.5, 5 mM
Dithiothreitol, 0.5% NP40, 60U/ml SUPERase Inhibitor
(Ambion), 5µl/ml protease inhibitors (Roche)). Lysates
were centrifuged at 4 °C, 5000×g for 5 min and the
supernatant collected. Fifty microlitres of supernatant was
collected as the input control. NaCl was added to eluates
to a ﬁnal concentration of 1M.
Biotin pull down
A volume of 25 μl of MyOne C1 Dynabeads (LifeTech)
was added per sample. Beads had been previously washed
with DEPC-treated 0.1M NaOH, 0.05M NaCl (twice
bead volume), and then washed once in DEPC-treated 0.1
M NaCl and once in hypotonic lysis buffer. Beads were
blocked with 1 μg/μl bovine serum albumin and 1 μg/μl
yeast tRNA prepared in hypotonic lysis buffer and rotated
for 3 h at 4 °C. Samples and beads were incubated for 30
min with rotation and then placed on a magnetic stand
and the remove supernatant removed. The beads were
washed three times with 200 μl of hypotonic lysis buffer.
RNA was extracted from the beads using a standard
Trizol extraction, and RNA was reverse transcribed into
cDNA for qPCR analysis. Data analysis was compared to
% of input controls.
Drug treatments
Temsirolimus, SF1670, bpV(HOpic) and bicalutamide
(Sigma, UK) were dissolved in dimethyl sulfoxide (DMSO;
10mM stock). These were diluted to 0–100 μM working
concentrations in media.
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